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The triad of substrate, trigger and transient excitation increase risk of SCD. MVP patients with scar have 7.7% risk of arrhythmic events compared to 2.5%. 2 Overall risk for SCD has been described around 0.4%. The patient received an ICD for secondary prevention of SCD.
DISCUSSION
MVP has been associated with SCD, necessitating a formal risk stratification strategy. This includes Holter monitor, CMR for scar and more recently PET is being studied to detect stage of inflammation. Above information can be used to guide decision and timing for Mitral valve intervention. Additionally, successful treatment with catheter ablation has been described. 
